Imperative Care, a medical technology company focused on advancing the treatment of thromboembolic disease, announced new findings from a pre-specified sex-specific analysis of the SYMPHONY-PE IDE Trial, published simultaneously in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) and presented by Aymen Ahmed, MD, of Endeavor Health Cardiovascular Institute, at Transcatheter Cardiovascular Therapeutics (TCT) 2026. The analysis found that women and men with intermediate-risk pulmonary embolism (PE) experienced substantial clot burden reduction, improvements in right-heart function, and broadly comparable short-term clinical and safety outcomes following aspiration thrombectomy with the Symphony Thrombectomy System, despite women demonstrating greater evidence of cardiac stress at baseline with similar initial clot burden.

“Previous studies have raised concerns about higher rates of bleeding and vascular complications among women undergoing procedures requiring large-bore vascular access, including advanced pulmonary embolism interventions. These concerns make the safety and effectiveness of large-bore thrombectomy in women an important clinical question,” said Arman Qamar, MD, MPH, senior and corresponding author of the study, Director of the Center for Cardiovascular Personalized Medicine and Co-Director of the Pulmonary Embolism Response Team at Endeavor Health Cardiovascular Institute.

“Our findings are particularly encouraging. Despite presenting with greater evidence of cardiac stress at baseline, women experienced substantial reductions in clot burden and improvements in right ventricular function, with clinical and safety outcomes broadly comparable to those observed in men. These prospective findings provide reassurance regarding the use of 24F pump-driven aspiration thrombectomy in women, while underscoring the need for larger studies to further evaluate sex-specific treatment responses and long-term outcomes,” added Dr. Qamar.